AG真人官方

On 14 July 2025, Range Resources Corporation (NYSE: RRC) filed a Form 8-K (Item 2.02) disclosing preliminary second-quarter 2025 hedging results.

• Total gain on derivatives: approximately $154.7 million for the three months ended 30 June 2025.
• Net cash receipts from derivative settlements: $31.5 million, broken down as $26.3 million from natural gas, $2.8 million from natural-gas-basis, $1.5 million from NGLs and $0.8 million from oil contracts.

The company emphasized that these figures are preliminary and will be finalized in the forthcoming Form 10-Q and related earnings release. No additional operating metrics were provided.

The sizeable mark-to-market gain and positive cash settlements are expected to enhance reported earnings and liquidity for Q2 2025, although such benefits are inherently volatile and tied to future commodity-price movements.

United Rentals, Inc. (NYSE: URI) and several international subsidiaries executed a Fifth Amended and Restated Credit Agreement on 10 July 2025, replacing their prior asset-based revolver.

The agreement establishes a senior secured $4.5 billion asset-based loan (ABL) facility backed by first-priority liens on substantially all U.S. and certain non-U.S. assets. A $175 million ANZ tranche, along with sub-limits of $250 million for Canada and $125 million for Rest-of-World borrowers, plus multiple swing-line and LC sub-limits, provide multi-currency flexibility (USD, CAD, EUR, GBP and others).

Maturity: 10 July 2030. Drawn as of 9 July 2025: $2.049 billion. Availability: roughly $2.428 billion (net of LCs) subject to borrowing-base limits.

Pricing ranges:

• SOFR / SONIA / EURIBOR / Term CORRA + 1.00%鈥�1.25%
• Base or Canadian prime + 0.00%鈥�0.25%
• Unused line fee: 0.20%

Covenants & Security: Standard negative covenants on debt, liens, dividends, investments and M&A. No ongoing financial covenant unless availability falls below 10% for five consecutive business days, at which point a 1.0脳 fixed-charge coverage ratio springs into effect. Guarantees are provided by Holdings and extensive U.S. and international subsidiaries, with collateral including equity pledges (65% limit on voting shares of foreign subs).

Strategic Impact: The new facility extends URI鈥檚 debt maturity profile by five years, increases global liquidity, and keeps covenant pressure light under normal operating conditions鈥攕upporting working-capital needs, fleet investment and potential bolt-on acquisitions.

Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company鈥檚 shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days鈥攗ntil 22-Dec-2025鈥攖o regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.

JPMorgan Chase Financial Company LLC is offering $1.554 million of Auto-Callable Contingent Interest Notes maturing 25 June 2030, fully and unconditionally guaranteed by JPMorgan Chase &Co. The notes are unsecured, unsubordinated debt that combine periodic coupon exposure with equity-index risk.

Income profile: Investors receive a Contingent Interest Payment of 2.50 % per quarter (10 % p.a.) for any Review Date on which both reference indices鈥攖he S&P 500 Equal Weight Index (SPW) and the EURO STOXX 50 Index (SX5E)鈥攃lose at or above their Interest Barriers (75 % of strike). If either index is below its barrier on a Review Date, no coupon is paid for that quarter.

Automatic call: If on any quarterly Review Date other than the final one both indices close at or above their original Strike Values (7,179.75 for SPW; 5,233.58 for SX5E), the notes are redeemed early for $1,000 principal + the current coupon. Thus the term can be as short as roughly three months.

Principal repayment: At maturity, provided the notes have not been called, investors receive:

• Par + final coupon if both indices are 鈮� their 70 % Trigger Values (5,025.825 for SPW; 3,663.506 for SX5E)
• Par reduced by the full downside of the lesser-performing index if either index finishes < its Trigger Value. A finish 鈮� 70 % results in loss of at least 30 % of principal; a worst-case 100 % decline would wipe out the investment.

Issue economics: Price to public is par; investors pay a built-in fee of $2 per $1,000 (0.20 %) plus embedded structuring/hedging costs. The bank鈥檚 estimated value is $975.20, implying an initial valuation discount of 2.48 % versus issue price.

Key calendar: Strike Date 20 Jun 2025; Pricing 23 Jun 2025; Settlement 26 Jun 2025. Twenty quarterly Review/Interest dates run through the final Review on 20 Jun 2030.

Material risks: Investors face issuer/guarantor credit risk, potential loss of principal, uncertain coupon payment, limited upside (maximum total coupon $500 per $1,000), lack of liquidity (no listing), valuation discount, and potential conflicts of interest arising from JPMorgan鈥檚 roles as issuer, guarantor, calculation agent, and hedging counterparty.

The notes may suit investors comfortable with equity-index downside risk and seeking above-market income, but unwilling to pay fixed coupons or accept full market participation. They are not appropriate for investors requiring capital preservation, assured income, or ready secondary-market liquidity.

Pasithea Therapeutics Corp. has filed a 424(b)(5) prospectus supplement dated June 20, 2025 to update its existing April 19, 2023 shelf registration and November 26, 2024 at-the-market (ATM) prospectus. The update reflects the Form S-3 Instruction I.B.6 limit that restricts primary offerings to one-third of public float when that float is below $75 million.

Key figures

• Maximum aggregate sales under ATM: $4.227 million (one-third of current $12.683 million public float).
• Already sold in the past 12 months: $2.075 million.
• Newly registered in this supplement: up to $2.151 million of common stock.
• Public float calculation date & price: April 25, 2025, 7,331,218 non-affiliate shares at $1.73 each.
• Latest market price (June 18, 2025): $0.7746 per share (Nasdaq: KTTA).

H.C. Wainwright & Co. will continue to act as sales agent or principal under the existing Sales Agreement. Pasithea remains both an emerging growth company and a smaller reporting company, allowing the issuer to avail itself of reduced disclosure obligations.

Because the company has already utilized about half of the permissible ATM capacity, this supplement ensures regulatory compliance and keeps the remaining $2.151 million capacity available for future opportunistic issuance. Investors should review previously disclosed risk factors for details on dilution, market volatility and other material risks.